Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Oak Ridge Investments LLC

Oak Ridge Investments LLC cut its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,822 shares of the pharmaceutical company’s stock after selling 77 shares during the quarter. Oak Ridge Investments LLC’s holdings in Vertex Pharmaceuticals were worth $854,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Telos Capital Management Inc. raised its stake in shares of Vertex Pharmaceuticals by 1.6% during the fourth quarter. Telos Capital Management Inc. now owns 15,073 shares of the pharmaceutical company’s stock worth $6,133,000 after purchasing an additional 237 shares during the last quarter. Brookstone Capital Management lifted its stake in shares of Vertex Pharmaceuticals by 11.1% in the 1st quarter. Brookstone Capital Management now owns 2,368 shares of the pharmaceutical company’s stock worth $990,000 after acquiring an additional 237 shares during the period. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Vertex Pharmaceuticals by 15.4% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 29,897 shares of the pharmaceutical company’s stock valued at $12,497,000 after acquiring an additional 3,999 shares in the last quarter. Brevan Howard Capital Management LP increased its stake in shares of Vertex Pharmaceuticals by 216.3% during the fourth quarter. Brevan Howard Capital Management LP now owns 4,830 shares of the pharmaceutical company’s stock worth $1,965,000 after acquiring an additional 3,303 shares during the period. Finally, Greenwood Capital Associates LLC raised its holdings in Vertex Pharmaceuticals by 11.3% during the fourth quarter. Greenwood Capital Associates LLC now owns 25,345 shares of the pharmaceutical company’s stock worth $10,313,000 after purchasing an additional 2,576 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs sold 7,073 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $448.00, for a total transaction of $3,168,704.00. Following the transaction, the director now owns 40,000 shares in the company, valued at approximately $17,920,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Bruce I. Sachs sold 7,073 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $448.00, for a total transaction of $3,168,704.00. Following the sale, the director now directly owns 40,000 shares in the company, valued at approximately $17,920,000. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Ourania Tatsis sold 2,350 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $439.11, for a total value of $1,031,908.50. Following the completion of the transaction, the executive vice president now owns 53,523 shares of the company’s stock, valued at approximately $23,502,484.53. The disclosure for this sale can be found here. Insiders have sold a total of 55,703 shares of company stock valued at $26,615,855 over the last ninety days. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Up 0.1 %

NASDAQ:VRTX traded up $0.63 during trading hours on Thursday, reaching $472.07. 665,718 shares of the company were exchanged, compared to its average volume of 1,215,019. The firm has a market cap of $121.82 billion, a price-to-earnings ratio of 30.59 and a beta of 0.39. The stock has a 50 day simple moving average of $480.92 and a 200 day simple moving average of $441.77. Vertex Pharmaceuticals Incorporated has a 52-week low of $340.83 and a 52-week high of $510.64. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.52 and a quick ratio of 2.26.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($12.54) by ($0.29). The firm had revenue of $2.65 billion for the quarter, compared to analysts’ expectations of $2.66 billion. Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. Vertex Pharmaceuticals’s revenue was up 6.1% on a year-over-year basis. During the same period last year, the firm posted $3.53 EPS. As a group, analysts predict that Vertex Pharmaceuticals Incorporated will post -1.83 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on VRTX shares. Redburn Atlantic initiated coverage on Vertex Pharmaceuticals in a research note on Thursday, June 27th. They set a “buy” rating and a $545.00 target price for the company. Truist Financial restated a “buy” rating and set a $550.00 target price (up from $508.00) on shares of Vertex Pharmaceuticals in a research report on Monday, August 5th. Wells Fargo & Company boosted their price objective on shares of Vertex Pharmaceuticals from $540.00 to $555.00 and gave the stock an “overweight” rating in a report on Monday, June 24th. TD Cowen increased their target price on shares of Vertex Pharmaceuticals from $450.00 to $500.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Finally, UBS Group reduced their price target on shares of Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating for the company in a research report on Wednesday, April 17th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $485.91.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.